Oct 19 (Reuters) - Sanofi SA SASY.PA:
SANOFI BREAKS GROUND ON NEW STATE-OF-THE-ART INSULIN MANUFACTURING FACILITY AT BIOCAMPUS IN FRANKFURT IN GERMANY
SANOFI - FULL INSULIN API PRODUCTION PLANNED FOR 2032
SANOFI - FRANKFURT BIOCAMPUS HAS 4,000 EMPLOYEES AND SUPPLIES 20 INSULIN PRODUCTS
Source text: ID: nGNX3J12yX
Further company coverage: SASY.PA
Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
